Publications & Presentations

SC administered-solrikitug demonstrated excellent tolerability, linear PK, expected bioavailability and low immunogenicity with marked and sustained eosinophil reduction in healthy participants.
 

The results of this study reflect solrikitug structure with its unmodified Fc region. 

This poster highlights the role of TSLP in experimental models of type 2 inflammatory diseases.

In vitro characterization of solrikitug, a differentiated anti-TSLP antibody, provides distinct epitope binding profile and superior potency compared to tezepelumab.

These data demonstrate that a surrogate for solrikitug reduces inflammation in a preclinical model of asthma, with solrikitug showing 10 times more potency than tezepelumab at inhibiting TSLP-induced human dendritic cell activation.